Which baseline labs should be ordered and monitored for a patient starting amlodipine or losartan, and when should the patient return for follow‑up and what symptoms would warrant an earlier call to the clinic?

Baseline Laboratory Monitoring for Amlodipine or Losartan

For patients starting amlodipine or losartan, obtain baseline serum creatinine, estimated GFR, serum potassium, and a lipid panel today; repeat potassium and creatinine in 1 month after starting losartan, but no routine lab monitoring is required for amlodipine alone.

Baseline Labs to Order Today

Essential Labs (Order for Both Medications)

• Serum creatinine and estimated GFR (eGFR) 1, 2, 1

  • Critical for losartan: identifies baseline renal function and risk for acute kidney injury
  • ARBs carry risk of acute renal failure, especially with bilateral renal artery stenosis 1, 2, 1
  • Patients with GFR <30 mL/min require dose adjustment or alternative therapy 1

• Serum potassium 1, 2, 3, 1

  • Mandatory for losartan: ARBs increase hyperkalemia risk, particularly in patients with CKD or those on potassium supplements 1, 2, 1
  • The 2021 ADA Diabetes Guidelines explicitly state: "serum creatinine and potassium should be monitored during treatment with an ACE inhibitor, ARB, or diuretic" 3
  • Not required for amlodipine monitoring (calcium channel blockers do not affect potassium) 1, 2

Cardiovascular Risk Assessment Labs

• Lipid panel (total cholesterol, LDL, HDL, triglycerides) 3, 4

  • Establishes baseline cardiovascular risk
  • Informs need for statin therapy (recommended for most adults 40-75 years with diabetes or 10-year ASCVD risk ≥10%) 3
  • Should be repeated annually 3

• Fasting glucose or HbA1c 4

  • Screens for diabetes, which affects BP targets and medication selection
  • Identifies patients requiring more intensive cardiovascular risk reduction

• Urine albumin-to-creatinine ratio 4

  • Detects early kidney disease
  • Losartan provides additional renoprotective benefits in diabetic nephropathy 5

Optional but Useful

• Serum uric acid 1, 2

  • Baseline reference if considering future diuretic therapy
  • Not affected by amlodipine or losartan

• Electrocardiogram 4

  • Screens for left ventricular hypertrophy and subclinical cardiovascular disease
  • Helps refine cardiovascular risk assessment

Follow-Up Laboratory Monitoring

For Losartan

Repeat serum creatinine and potassium in 1 month 1, 3, 1

• The 2017 ACC/AHA Guidelines specify monitoring "during treatment" with ARBs, particularly for hyperkalemia and acute kidney injury 1
• Critical window: first 4-12 weeks after initiation or dose change 3
• If stable: repeat every 3-6 months, or annually if no risk factors 3, 6
• More frequent monitoring needed if:
  • Baseline GFR <60 mL/min 3
  • Diabetes present 3
  • Concurrent use of NSAIDs, potassium supplements, or potassium-sparing diuretics 1, 5
  • Elderly patients 5

For Amlodipine

No routine laboratory monitoring required 1, 2, 1

• Calcium channel blockers do not cause electrolyte disturbances or affect renal function
• Annual lipid panel and glucose screening remain appropriate for cardiovascular risk assessment 3, 4

When Should the Patient Return?

Schedule follow-up in 1 month 2, 6, 2

The 2017 ACC/AHA Guidelines state: "Patients receiving antihypertensive drug treatment should be seen monthly or every 2 months, depending on the level of BP, until readings on 2 consecutive visits are below their target" 2, 6, 2

At the 1-Month Visit:

• Recheck blood pressure (office or home readings)
• Repeat potassium and creatinine if on losartan
• Assess medication adherence and side effects
• Titrate dose if BP not at goal (<140/90 mmHg for most patients, <130/80 mmHg for high-risk patients) 2

Once BP is Controlled:

• Follow-up every 3-6 months 2, 6, 2
• Annual comprehensive labs (lipids, glucose, creatinine, potassium) 3, 4

Call Clinic Sooner If:

Losartan-Specific Warning Signs

Call immediately for:

• Angioedema: swelling of face, lips, throat, or tongue (medical emergency) 1, 5
• Severe hypotension: dizziness, lightheadedness, fainting 5
• Signs of hyperkalemia: muscle weakness, irregular heartbeat, palpitations 1, 5
• Acute kidney injury: decreased urination, swelling in feet/ankles, unexplained weight gain 5

Call within 1-2 days for:

• Persistent dizziness or lightheadedness
• Severe fatigue
• Chest pain 5
• Severe diarrhea or vomiting (risk of dehydration and acute kidney injury) 5

Amlodipine-Specific Warning Signs

Call immediately for:

• Worsening angina or new chest pain (rare paradoxical effect when initiating therapy) 7
• Severe hypotension: extreme dizziness, fainting 7
• Irregular or very fast heartbeat (arrhythmia, palpitations) 7

Call within 1-2 days for:

• Significant ankle/leg swelling (dose-related pedal edema, more common in women) 1, 2, 7
• Severe flushing or hot feeling in face 7
• Extreme sleepiness or fatigue 7

Common Pitfalls to Avoid

1. Don't skip potassium monitoring with losartan: Hyperkalemia is a serious risk, especially in patients with CKD, diabetes, or concurrent use of NSAIDs 1, 3, 1

2. Don't assume amlodipine needs the same monitoring as losartan: Calcium channel blockers do not affect electrolytes or renal function 1, 2

3. Don't delay follow-up beyond 1 month: Early assessment ensures BP control and identifies adverse effects before they become serious 2, 6, 2

4. Don't ignore ankle swelling with amlodipine: While common and usually benign, significant edema may require dose reduction or medication change 1, 7

5. Don't combine losartan with ACE inhibitors or direct renin inhibitors: This combination is potentially harmful and not recommended 1